(Q24202961)

ORCID Public Data File 2021

author name string

Kate Cahill

series ordinal

1

0 references

Sarah Stevens

series ordinal

2

0 references

Tim Lancaster

series ordinal

4

0 references

language of work or name

English

0 references

publication date

31 May 2013

0 references

published in

Cochrane Database of Systematic Reviews

0 references

issue

5

0 references

page(s)

CD009329

0 references

cites work

Antidepressants for smoking cessation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Anxiolytics for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Clonidine for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Lobeline for smoking cessation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Mecamylamine (a nicotine antagonist) for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Nicobrevin for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Nicotine receptor partial agonists for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Nicotine vaccines for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Nicotine replacement therapy for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Opioid antagonists for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Cannabinoid type 1 receptor antagonists for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Silver acetate for smoking cessation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Smoking cessation for chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Interventions for smoking cessation in hospitalised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Internet-based interventions for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Community pharmacy personnel interventions for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Interventions for preoperative smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Interventions for promoting smoking cessation during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Reduction versus abrupt cessation in smokers who want to quit

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Relapse prevention interventions for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Interventions for smoking cessation and reduction in individuals with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Interventions for preventing weight gain after smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Workplace interventions for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Grading quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Serious adverse reactions of bupropion for smoking cessation: analysis of the French Pharmacovigilance Database from 2001 to 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Pharmacological interventions for promoting smoking cessation during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Interventions for smokeless tobacco use cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

The impact of pharmaceutical company funding on results of randomized trials of nicotine replacement therapy for smoking cessation: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Interventions for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Tobacco dependence and the nicotine patch. Clinical guidelines for effective use

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

A meta-analysis to assess the incidence of adverse effects associated with the transdermal nicotine patch

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Psychiatric adverse events associated with varenicline: an intensive postmarketing prospective cohort study in New Zealand

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Cardiovascular events in patients taking varenicline: a case series from intensive postmarketing surveillance in New Zealand

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Bupropion and the risk of sudden death: a self-controlled case-series analysis using The Health Improvement Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

The need for dissemination of evidence-based results from research on nicotine and tobacco

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

The Safety of Transdermal Nicotine as an Aid to Smoking Cessation in Patients with Cardiac Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Safety issues in pharmacotherapy for smoking in patients with cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Safety and drug utilization profile of varenicline as used in general practice in England: interim results from a prescription-event monitoring study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Inhibition of CYP2D6 activity by bupropion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Bupropion and cognitive behavioral therapy for weight-concerned women smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Combination of direct and indirect evidence in mixed treatment comparisons

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Safety and effectiveness of transdermal nicotine patch in smokers admitted with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Neuropsychiatric events in varenicline and nicotine replacement patch users in the Military Health System.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation. A systematic review and meta-analysis of one hundred and twenty studies involving 177,390 individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Comparisons of high-dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: a systematic review and multiple treatment meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Efficacy and safety of pharmacotherapy for smoking cessation among pregnant smokers: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Transdermal Nicotine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an aid to smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Nicotine replacement and behavioral therapy for smoking cessation in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Full publication of results initially presented in abstracts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Bayesian measures of model complexity and fit

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Biochemical verification of tobacco use and cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Efficacy of a nicotine mouth spray in smoking cessation: a randomised, double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Smoking cessation interventions for smokers with current or past depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Automating network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

The long-term effect of nicotine on the oral mucosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

A double-blind study evaluating the long-term safety of varenicline for smoking cessation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Effectiveness of smoking cessation therapies: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

Bupropion for smoking cessation in patients with acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

7 January 2021

inferred from DOI database lookup

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

7 January 2021

inferred from DOI database lookup

A prospective safety surveillance study for bupropion sustained-release in the treatment of depression.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009329.PUB2

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1002/14651858.CD009329.PUB2

1 reference

Consolidated OpenCitations Corpus – April 2017

release_bq3za3i7cjbjbit4eof3vik56q

974612

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/bq3za3i7cjbjbit4eof3vik56q

24 November 2022

mapped directly with Wikidata item

974612

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference